Positive allosteric modulators of the μ‐opioid receptor: a novel approach for future pain medications
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Morphine and other agonists of the μ‐opioid receptor are used clinically for acute and chronic pain relief and are considered to be the gold standard for pain medication. However, these opioids also have significant side effects, which are also mediated via activation of the μ‐opioid receptor. Since the latter half of the twentieth century, researchers have sought to tease apart the mechanisms underlying analgesia, tolerance and dependence, with the hope of designing drugs with fewer side effects. These efforts have revolved around the design of orthosteric agonists with differing pharmacokinetic properties and/or selectivity profiles for the different opioid receptor types. Recently, μ‐opioid receptor‐positive allosteric modulators (μ‐ PAMs ) were identified, which bind to a (allosteric) site on the μ‐opioid receptor separate from the orthosteric site that binds an endogenous agonist. These allosteric modulators have little or no detectable functional activity when bound to the receptor in the absence of orthosteric agonist, but can potentiate the activity of bound orthosteric agonist, seen as an increase in apparent potency and/or efficacy of the orthosteric agonist. In this review, we describe the potential advantages that a μ‐ PAM approach might bring to the design of novel therapeutics for pain that may lack the side effects currently associated with opioid therapy. Linked Articles: This article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue-2
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthes, H. W. D., Maldonado, R., Simonin, F., Valverde, O., Slowe, S., Kitchen, I., Befort, K., Dierich, A., Le Meur, M., Dollé, P., et al. (1996) · Nature · doi:10.1038/383819a0 · Cited by 1,722 · cited 2×
“Morphine-induced analgesia is lost in mice lacking the μ-opioid receptor gene (Matthes et al., 1996).”
BackgroundAllosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance
Williams, J. T., Ingram, S. L., Henderson, G., Chavkin, C., von Zastrow, M., Schulz, S., Koch, T., Evans, C. J., & Christie, M. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005942 · Cited by 802
Waldhoer, M., Bartlett, S. E., & Whistler, J. L. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073940 · Cited by 740
DeWire, S. M., Yamashita, D. S., Rominger, D. H., Liu, G., Cowan, C. L., Graczyk, T. M., Chen, X.-T., Pitis, P. M., Gotchev, D., Yuan, C., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201616 · Cited by 647 · cited 1×
“Indeed, Trevena have recently identified a G protein-biased agonist of the μ-opioid receptor, TRV130, which is reported to be a potent analgesic but with reduced gastrointestinal and respiratory dysfunctional effects compared with morphine (Dewire et al., 2013).”
BackgroundOpioid receptors: Distinct roles in mood disorders
Lutz, P.-E., & Kieffer, B. L. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2012.11.002 · Cited by 542
Emerging paradigms in GPCR allostery: implications for drug discovery
Wootten, D., Christopoulos, A., & Sexton, P. M. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4052 · Cited by 498 · cited 2×
“these have been recently reviewed elsewhere (Koole et al., 2010; Keov et al., 2011; Davey et al., 2012; Kenakin and Christopoulos, 2013; Wootten et al., 2013).”
BackgroundSubtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders
Conn, P. J., Jones, C. K., & Lindsley, C. W. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.12.002 · Cited by 286
Constitutive μ-Opioid Receptor Activity Leads to Long-Term Endogenous Analgesia and Dependence
Corder, G., Doolen, S., Donahue, R. R., Winter, M. K., Jutras, B. L., He, Y., Hu, X., Wieskopf, J. S., Mogil, J. S., Storm, D. R., et al. (2013) · Science · doi:10.1126/science.1239403 · Cited by 240 · cited 1×
“Recently, opioid receptor antagonists were also shown to increase hyperalgesia in acute and chronic inflammatory pain models in mice that had not been treated with exogenous opioids (Corder et al., 2013).”
BackgroundPharmacology of opioids in the treatment of chronic pain syndromes
Vallejo, R. (2011) · Pain Physician · doi:10.36076/ppj.2011/14/e343 · Cited by 124
Cited by
Untangling the complexity of opioid receptor function
Valentino, R. J., & Volkow, N. D. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0225-3 · Cited by 383
Neuropeptide oxytocin enhances μ opioid receptor signaling as a positive allosteric modulator
Meguro, Y., Miyano, K., Hirayama, S., Yoshida, Y., Ishibashi, N., Ogino, T., Fujii, Y., Manabe, S., Eto, M., Nonaka, M., et al. (2018) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2018.04.002 · Cited by 68
Opioid addiction: who are your real friends?
Eitan, S., Emery, M. A., Bates, M. L. S., & Horrax, C. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.05.017 · Cited by 42
Metadata
- Authors
- Burford, N. T., Traynor, J. R., & Alt, A.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2014-07
- Volume
- 172
- Issue
- 2
- Pages
- 277-286
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1922816396
- Cited by
- 112
- References
- 10
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.